Clean Science and Technology Limited — Q3 FY26 earnings call

Call held 31 Jan 2026

Management summary

Clean Science reported a challenging Q3 FY26 with consolidated revenue moderating to ₹216 crores, a 10% sequential decline, and a 21% YoY decline in sales primarily due to volume softness and pricing pressure. Consolidated EBITDA and PAT margins stood at 33% and 21% respectively. Despite headwinds from Chinese competition and tariffs, the HALS business showed strong 55% YoY growth and achieved EBITDA breakeven in its subsidiary. The company is focused on operational discipline, new product commercialization, and maintaining market share amidst evolving market conditions.

Highlights

  • Stand-alone revenue moderated to ₹180 crores.

  • Stand-alone EBITDA margin at 40% and PAT margin at 29%.

  • Consolidated revenue moderated by 10% QoQ to ₹216 crores.

  • Consolidated EBITDA margin at 33% and PAT margin at 21%.

  • HALS business delivered robust 55% Y-o-Y sales growth.

  • HALS subsidiary (Clean Fino Chem Limited) achieved EBITDA breakeven.

  • 9-month Y-o-Y revenue declined by 10% from ₹668 crores to ₹602 crores.

  • Interim dividend of ₹2 per share approved.

Concerns

  • Challenging and uncertain business environment (muted customer offtake, pricing pressure, tariff-related uncertainties, incremental capacities in China).

  • Loss of key customer in FMCG segment (4-MAP) due to backward integration in China.

  • Impact of tariffs (e.g., 55% tariff on avobenzone in US) on Indian end-customers, leading to reduced demand.

  • Chinese overcapacity and aggressive pricing in hydroquinone and MEHQ.

Key financials

  1. Consolidated Revenue ₹216 Cr -21%YoY
  2. Consolidated EBITDA Margin 33%
  3. Consolidated PAT Margin 21%
  4. HALS Sales Growth 55%
  5. 9-Month Revenue ₹602 Cr -10%YoY

What they filed

Q1 FY27: revenue down 5.9%, net profit down 5.2% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue228 232 245 220 213 −7%185 −20%197 −20%207 −6%
EBITDA95 102 105 101 92 −3%72 −29%88 −16%87 −14%
Net profit67 74 79 77 65 −3%52 −30%58 −27%73 −5%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Sales Profile
    72% Performance Chemical21% Pharma Agro5% FMCG
  • HALS Business
    810 tons Volume5% Revenue Growth₹425/kg Blended Realization

Guidance & targets

Capex

  • Performance Chemical 2 commercialization Capex · Q1 FY27 · High confidence Q1 FY'27

    Previously March 2026 → Q1 FY'27

    Further capex time line of Performance Chemical 2 is as per plan, and we expect to commercialize in Q1 FY '27... Yes. I think we had anticipated that we will start the production in March. But now we feel with the current scenario, we'll start by May. So there has been a 2 month a 60-day delay, probably another 15-odd days for water trials and commissioning. So yes, there has been a quarter delay; yes, you're right.

    — Siddharth Sikchi

Capacity

  • New product utilization (HALS) Capacity · over a 2-year period · Medium confidence around 50%
    And our target remains like that's typically with any new product which we are commercializing at least around 50% of utilization over a 2-year period.

    — Management

Market Share

  • Retain market share Market Share · Long term · High confidence —
    But alongside the endeavor is also to retain our market share in the segments because it has taken us 20 long years to build these markets, to retain these customers.

    — Siddharth Sikchi

New Products

  • Bringing new products online New Products · As quickly as possible · High confidence —
    working towards improving the margins, improving the revenues, bringing new products online as quickly as possible

    — Siddharth Sikchi

Profitability

  • EBITDA margin stabilization Profitability · Next quarter or end of next quarter · Low confidence —
    it would be appropriate to wait for at least for a quarter to really understand where we stand. So probably in the next quarter or the end of the next quarter, we can have this discussion, please.

    — Siddharth Sikchi

Exports

  • HALS export mix Exports · Q4 and subsequently in '27 · Medium confidence Ramping up quickly
    you will start seeing as we move in quarter 4 and then subsequently in '27, this mix will start changing, and we expect the exports to quickly start ramping up.

    — Siddharth Sikchi

Risks & concerns

  • Challenging and uncertain business environment (muted customer offtake, pricing pressure, tariff-related uncertainties, incremental capacities in China).

    high

    These conditions have continued from Q2 and impacted revenue and profitability.

    Management acknowledged

  • Loss of key customer in FMCG segment (4-MAP) due to backward integration in China.

    high

    This is a permanent loss, and the company is evaluating how to utilize the affected facility.

    Management acknowledged

  • Impact of tariffs (e.g., 55% tariff on avobenzone in US) on Indian end-customers, leading to reduced demand.

    high

    Indian customers buying 4-MAP have slowed down dramatically due to US tariffs on their end product.

    Management acknowledged

  • Chinese overcapacity and aggressive pricing in hydroquinone and MEHQ.

    high

    Chinese players have lowered hydroquinone prices to all-time lows, forcing Clean Science to reduce MEHQ prices to compete and maintain volumes.

    Management acknowledged

  • Delays in commercialization of Performance Chemical 2.

    medium

    Production start delayed from March to May, resulting in a quarter delay for revenue generation.

    Management acknowledged

Areas of evasion (2)

  • Specific future revenue projections for new projects
  • Detailed breakdown of revenue loss by customer/product

Q&A highlights

2 direct
Future revenue from new Performance Chemical projects and HALS volumes/realizations. Partial
So typically, in these fluid market conditions, we would avoid giving any forward-looking statements. But to just pinpoint with the Performance Chemical 1 because of the prices reduction overall, the -- around 80% capacity utilization, we are looking at a revenue of INR260 crores, which was earlier INR320-odd crores.

Management explicitly declined to give forward revenue guidance for new projects, citing 'fluid market conditions,' signaling high uncertainty, though current HALS metrics were provided.

Asked by Jason Soans

Impact of China's aggressive pricing and tariffs on MEHQ, BHA, and 4-MAP, and the sustainability of current margins. Direct
Now because the Chinese have lowered the prices of hydroquinone all-time low price and hence, the conventional process of hydroquinone to MEHQ makes MEHQ also at a lower cost point. To attribute to this, we have no choice but to lower our prices of MEHQ to compete with these emerging players of hydroquinone-derived MEHQ in China.

This exchange directly addresses the core reasons for margin pressure and volume decline, highlighting intense competitive pressure from China and tariff impacts on end-user demand.

Asked by Sanjesh Jain

Promoter's long-term commitment and potential for further share dilution after the 3-year lock-in period. Direct
So in my view, there will not be any further dilution by the Boob Family in the next couple of years... See, it is a very subjective decision by the family, I mean, by the Boob family. I cannot really comment, but unlikely that they will even sell beyond 3 years.

This question probes a sensitive area for investors regarding promoter commitment and potential future share overhang, with management providing a reassuring, though ultimately non-binding, statement.

Asked by Abhijit Akella

2 min read 6 chapters

Detailed narrative

Q3 FY26 Financial Performance Overview

Clean Science reported a challenging Q3 FY26, with stand-alone revenue at ₹180 crores, yielding an EBITDA of ₹72 crores (40% margin) and PAT of ₹52 crores (29% margin). On a consolidated basis, revenue moderated by 10% sequentially to ₹216 crores, marking a 21% year-on-year decline primarily driven by volume softness. Consolidated EBITDA and PAT margins stood at 33% and 21% respectively, translating to an EBITDA of ₹72 crores and PAT of ₹46 crores. For the first nine months of FY26, revenue declined by 10% year-on-year, from ₹668 crores to ₹602 crores.

HALS Business Resilience and Growth

Despite the overall challenging environment, the HALS business demonstrated robust performance, achieving a 55% year-on-year growth in sales. Sequentially, HALS volumes grew by 6.5% to approximately 810 tons, with a blended realization of ₹425 per kg, largely driven by HALS 770. A significant milestone was the achievement of EBITDA breakeven in the subsidiary, Clean Fino Chem Limited, indicating improving operational efficiency and product mix, with HALS 944 contributing nearly 20% to the HALS portfolio.

Impact of Chinese Competition and Tariffs

The company faced significant headwinds from aggressive Chinese competition, particularly in hydroquinone, which led to an all-time low in MEHQ prices. Clean Science was compelled to reduce its MEHQ prices to remain competitive and retain market share. Additionally, tariffs, such as the 55% duty on avobenzone in the United States, severely impacted Indian end-customers of 4-MAP, leading to a dramatic slowdown in demand and the permanent loss of a key customer in China due to backward integration.

Capex and New Product Commercialization

Clean Science is progressing with its capex plans, having commercialized its new hydroquinone and catechol plant in December, with customer trials ongoing. This is expected to provide immediate margin benefits for downstream products like TBHQ and Veratrole. The Performance Chemical 2 plant, however, experienced a delay, with commercialization now expected in Q1 FY27, pushed from an earlier target of March to May. The company has infused ₹150 crores into its subsidiary over the last nine months, bringing the total investment to around ₹700 crores.

Product Mix and Segment Performance

The sales profile for Q3 FY26 showed Performance Chemicals as the largest segment, contributing 72% of revenue, followed by Pharma Agro at 21%, and FMCG at 5%. The Performance segment was most affected by volume-led declines in MEHQ and BHA. The contribution of the top 4 products to stand-alone revenue declined to 75% from 80% in the previous quarter, indicating a shift in product mix and softer demand for some established products.

Outlook and Strategic Focus

Given the fluid market conditions, management deferred specific EBITDA margin guidance, stating it would be appropriate to reassess in the next quarter or two. The company's strategy involves optimizing costs, bringing new products online, and maintaining market share amidst external challenges. While acknowledging the impact of macroeconomics beyond their control, management expressed confidence in their long-term strategy, supported by a healthy cash flow of ₹450 crores and continued R&D efforts.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Chemicals earnings calls